Evidence map›Paper›PMID 28449705›Full record

ArticleBMC pharmacology & toxicology2017

Large-scale detection of drug off-targets: hypotheses for drug repurposing and understanding side-effects.

Matthieu Chartier, Louis-Philippe Morency, María Inés Zylber, Rafael J Najmanovich

Open access · goldAbstract read
In one paragraph

Article in BMC pharmacology & toxicology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 62 citations in OpenAlex.

  1. A review of the current anti-New microbes and new infections · 2026
    Review
  2. Article
  3. Rare Disease Drug Repurposing.JAMA network open · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Docking-Based Virtual Screening Enables Prioritizing Protein Kinase Inhibitors WithFrontiers in cellular and infection microbiology · 2022
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Molecular networks in Network Medicine: Development and applications.Wiley interdisciplinary reviews. Systems biology and medicine · 2020
    Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Matthieu ChartierDepartment of Biochemistry, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Québec, Canada.
Louis-Philippe MorencyDepartment of Biochemistry, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Québec, Canada.
María Inés ZylberDepartment of Biochemistry, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Québec, Canada.
Rafael J NajmanovichDepartment of Biochemistry, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Québec, Canada. rafael.najmanovich@umontreal.ca.
Université de Sherbrooke · CAUniversité de Montréal · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPromiscuity in molecular interactions between small-molecules, including drugs, and proteins is widespread. Such unintended interactions can be exploited to suggest drug repurposing possibilities as well as to identify potential molecular mechanisms responsible for observed side-effects.

methodsWe perform a large-scale analysis to detect binding-site molecular interaction field similarities between the binding-sites of the primary target of 400 drugs against a dataset of 14082 cavities within 7895 different proteins representing a non-redundant dataset of all proteins with known structure. Statistically-significant cases with high levels of similarities represent potential cases where the drugs that bind the original target may in principle bind the suggested off-target. Such cases are further analysed with docking simulations to verify if indeed the drug could, in principle, bind the off-target. Diverse sources of data are integrated to associated potential cross-reactivity targets with side-effects.

resultsWe observe that promiscuous binding-sites tend to display higher levels of hydrophobic and aromatic similarities. Focusing on the most statistically significant similarities (Z-score ≥ 3.0) and corroborating docking results (RMSD < 2.0 Å), we find 2923 cases involving 140 unique drugs and 1216 unique potential cross-reactivity protein targets. We highlight a few cases with a potential for drug repurposing (acetazolamide as a chorismate pyruvate lyase inhibitor, raloxifene as a bacterial quorum sensing inhibitor) as well as to explain the side-effects of zanamivir and captopril. A web-interface permits to explore the detected similarities for each of the 400 binding-sites of the primary drug targets and visualise them for the most statistically significant cases.

conclusionsThe detection of molecular interaction field similarities provide the opportunity to suggest drug repurposing opportunities as well as to identify potential molecular mechanisms responsible for side-effects. All methods utilized are freely available and can be readily applied to new query binding-sites. All data is freely available and represents an invaluable source to identify further candidates for repurposing and suggest potential mechanisms responsible for side-effects.

Indexed as

Drug-Related Side Effects and Adverse ReactionsDrug RepositioningOff-Label UseBinding SitesDatasets as TopicHumansPharmaceutical PreparationsProteinsPharmaceutical PreparationsProteinsBinding-site similaritiesCross-reactivityDrug repurposingLarge-scale analysisMolecularinteraction field similaritiesPromiscuitySide-effects

Identifiers

PMID28449705
PMCPMC5408384
OpenAlexW2592476227

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.